Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • Tuesday
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines ConferenceGlobeNewsWire • Monday
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewsWire • 09/26/24
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease StudyZacks Investment Research • 09/25/24
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewsWire • 09/24/24
Wave Life Sciences' stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trialMarket Watch • 09/24/24
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 SkippingGlobeNewsWire • 09/24/24
Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/08/24
Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024GlobeNewsWire • 08/01/24
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's DiseaseGlobeNewsWire • 06/25/24
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA EditingGlobeNewsWire • 06/12/24
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/09/24
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific OfficerGlobeNewsWire • 05/09/24
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/07/24
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024GlobeNewsWire • 05/02/24
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 04/30/24
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA EditingGlobeNewsWire • 04/23/24